Anavex Life Sciences shares were up 7% to $11.25 after the company said it saw positive trial results for its oral blarcamesine for the treatment of early Alzheimer's disease. The clinical-stage ...
About half of new patients will survive another five years after being diagnosed with dementia ... to determine the potential benefits of new treatments that aim to slow the progression of ...
Suffering from another attack of cystitis? Don't despair, we've rounded up the best alternative treatments designed to bring instant relief to your symptoms. Here, we present three more natural cures.
Join host Jim Burneka and his guest, Dr. Kerry Ramella, as they discuss evidence-based mental health treatments beyond traditional talk therapy. Their discussion covers the following: ...
On track to report data from Phase 1 clinical trial evaluating VG-3927 for Alzheimer’s disease in 1Q 2025, providing critical insights into treatment options. Final analysis from IGNITE Phase 2 ...
Posdinemab, a monoclonal antibody targeting phosphorylated tau, is currently in a Phase 2b trial named "AuTonomy" for early Alzheimer's disease patients. The treatment aims to slow the spread of ...